Global Lymphoma Treatments Market Size is estimated to reach $13.4 billion by 2027 and it is poised to grow at a CAGR of 8.3% over the forecast period of 2022-2027. Lymphomas belong to the category of blood cancers, and thus
a substantial proportion of the world population suffers from the following
form of cancer. New treatments of lymphoma are supported by the rising R&D
expenditure by major pharmaceutical companies - that are following aggressive
norms to find a long-term cure with alleviated patient comfort. Skin lymphomas
can be treated by utilizing targeted therapy, chemotherapy, immunotherapy, and various
forms of drug inhibitors that control or put the lymphoma into remission. The
cost to treat lymphoma varies as per region, however, medical tourism
facilities alleviate the traffic to countries such as India, which boost the
global lymphoma treatment market. .
Lymphoma Treatments Market Drivers
The Alleviating Cases of Lymphomas Across the Regions has Fuelled the Marketplace
A critical facet of the growing treatment market for lymphomas is a growing patient pool afflicted with the following. Further, as per analysis from the Frontiers.Org, the age-standardized rate of non-Hodgkin Lymphoma has shown an increasing trend globally from the 1990s to 2019, with an EPAC of 0.56. Meanwhile, increasing trends were observed in both sexes and most geographic regions, particularly in East Asia (EAPC = 3.57, 95% CI: 3.29–3.86).
The Substantial Lymphoma Cure Rates have Driven the Market Growth
As per the American Cancer Society in 2020, an estimated 77,240 individuals underwent diagnostics for NHL. Moreover, the 5-year survival rate for NHL now stands at 73%, which provides optimal opportunities to the patient and healthcare system to provide a cure at the right time. Additionally, a growing initiative in R&D of developing advanced therapies to treat a wide range of lymphomas will help various sub-classes, such as the mantle cell lymphoma treatment market, and follicular lymphoma treatment market, amongst others.
Market Approvals and Clinical Trials
In June 2021, Novartis announced strong trial data from the analysis of the pivotal phase II ELARA Trial of KYMIRAH, with patients suffering from relapsed or refractory to cure follicular lymphoma. In September 2022, Gilead’s Kite-CAR T Cell Therapy – YESCARTA became the first in Europe to receive a Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma. 41% of the patients demonstrated event-free survival at two years versus 16% who received standard care.
The Major Players in The Market Include
The Major Players in the Lymphoma Treatment Market include Takeda Pharmaceutical Company, AstraZeneca, Bayer AG, Novartis AG, Kite Pharmaceuticals, Spectrum Pharmaceuticals, Teva Pharmaceuticals, Merck and Co, AbbVie Inc, and Janssen Pharmaceuticals.
The patent cliffs of popular drugs for treatment will offer opportunities to marketers. Further, newer entrants and existing companies will both accomplish growth due to the following reason. Developed regions such as the U.S., the UK and Germany amongst others will continue to hold the baton for development and market growth for the forecast period of 2022-2027.